{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:47:54Z","timestamp":1791668874886,"version":"4.3.4"},"reference-count":34,"publisher":"Society of Nuclear Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.2967\/jnumed.122.264597","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T21:25:58Z","timestamp":1675373158000},"page":"873-879","source":"Crossref","is-referenced-by-count":8,"title":["Signaling Network Response to \u03b1-Particle\u2013Targeted Therapy with the<sup>225<\/sup>Ac-Labeled Minigastrin Analog<sup>225<\/sup>Ac-PP-F11N Reveals the Radiosensitizing Potential of Histone Deacetylase Inhibitors"],"prefix":"10.2967","volume":"64","author":[{"given":"Yun","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Imobersteg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Chiorazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Schibli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin P.","family":"B\u00e9h\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Grzmil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"2023060112150625000_64.6.873.1","doi-asserted-by":"crossref","unstructured":"Grzmil M Meisel A Beh\u00e9 M Schibli R . An overview of targeted radiotherapy. In: Lewis JS Windhorst AD Zeglis BM , eds. Radiopharmaceutical Chemistry. Springer International Publishing; 2019:85\u2013100.","DOI":"10.1007\/978-3-319-98947-1_5"},{"key":"2023060112150625000_64.6.873.2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/ph12030114","article-title":"Lutathera\u00ae: the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy","volume":"12","author":"Hennrich","year":"2019","journal-title":"Pharmaceuticals (Basel)."},{"key":"2023060112150625000_64.6.873.3","first-page":"13N","volume":"63(5)","author":"FDA approves Pluvicto\/Locametz for metastatic castration-resistant prostate cancer","year":"2022","journal-title":"J Nucl Med."},{"key":"2023060112150625000_64.6.873.4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.186338"},{"key":"2023060112150625000_64.6.873.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178673"},{"key":"2023060112150625000_64.6.873.6","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3390\/pharmaceutics12111088","article-title":"Evaluation of actinium-225 labeled minigastrin analogue [225Ac]Ac-DOTA-PP-F11N for targeted alpha particle therapy","volume":"12","author":"Qin","year":"2020","journal-title":"Pharmaceutics."},{"key":"2023060112150625000_64.6.873.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.233031"},{"key":"2023060112150625000_64.6.873.8","first-page":"485","article-title":"In vitro and in\u00a0vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging","volume":"45","author":"Aloj","year":"2004","journal-title":"J Nucl Med."},{"key":"2023060112150625000_64.6.873.9","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz984"},{"key":"2023060112150625000_64.6.873.10","first-page":"5165","article-title":"Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in\u00a0vitro and in\u00a0vivo","volume":"60","author":"Butler","year":"2000","journal-title":"Cancer Res."},{"key":"2023060112150625000_64.6.873.11","doi-asserted-by":"crossref","first-page":"10861","DOI":"10.7150\/thno.45440","article-title":"Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [177Lu]Lu-PP-F11N","volume":"10","author":"Grzmil","year":"2020","journal-title":"Theranostics."},{"key":"2023060112150625000_64.6.873.12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088239"},{"key":"2023060112150625000_64.6.873.13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat Rev Drug Discov."},{"key":"2023060112150625000_64.6.873.14","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S1470-2045(17)30379-0","article-title":"Targeted radionuclide therapy in combined-modality regimens","volume":"18","author":"Gill","year":"2017","journal-title":"Lancet Oncol."},{"key":"2023060112150625000_64.6.873.15","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1038\/s41467-020-17336-9","article-title":"Proteome activity landscapes of tumor cell lines determine drug responses","volume":"11","author":"Frejno","year":"2020","journal-title":"Nat Commun."},{"key":"2023060112150625000_64.6.873.16","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.3390\/cancers12092430","article-title":"Cross-species proteomics identifies CAPG and SBP1 as crucial invasiveness biomarkers in rat and human malignant mesothelioma","volume":"12","author":"Nader","year":"2020","journal-title":"Cancers (Basel)."},{"key":"2023060112150625000_64.6.873.17","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.RA120.002046"},{"key":"2023060112150625000_64.6.873.18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.256263"},{"key":"2023060112150625000_64.6.873.19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209417"},{"key":"2023060112150625000_64.6.873.20","doi-asserted-by":"publisher","DOI":"10.1111\/febs.13061"},{"key":"2023060112150625000_64.6.873.21","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.chembiol.2017.08.015","article-title":"Divergent JNK phosphorylation of HDAC3 in triple-negative breast cancer cells determines HDAC inhibitor binding and selectivity","volume":"24","author":"Hanigan","year":"2017","journal-title":"Cell Chem Biol."},{"key":"2023060112150625000_64.6.873.22","doi-asserted-by":"publisher","DOI":"10.1080\/09553000110066068"},{"key":"2023060112150625000_64.6.873.23","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00259-019-04499-x","article-title":"Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours","volume":"47","author":"Adant","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023060112150625000_64.6.873.24","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3719"},{"key":"2023060112150625000_64.6.873.25","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/nar\/gkz1139","article-title":"53BP1\/RIF1 signaling promotes cell survival after multifractionated radiotherapy","volume":"48","author":"Eke","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"2023060112150625000_64.6.873.26","doi-asserted-by":"publisher","DOI":"10.1126\/science.281.5383.1677"},{"key":"2023060112150625000_64.6.873.27","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206677"},{"key":"2023060112150625000_64.6.873.28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-0173"},{"key":"2023060112150625000_64.6.873.29","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/17.15.4426"},{"key":"2023060112150625000_64.6.873.30","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2694"},{"key":"2023060112150625000_64.6.873.31","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-08-0084"},{"key":"2023060112150625000_64.6.873.32","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1272"},{"key":"2023060112150625000_64.6.873.33","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1021\/acs.molpharmaceut.9b00512","article-title":"Enhancing the efficacy of melanocortin 1 receptor-targeted radiotherapy by pharmacologically upregulating the receptor in metastatic melanoma","volume":"16","author":"Li","year":"2019","journal-title":"Mol Pharm."},{"key":"2023060112150625000_64.6.873.34","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0011"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.122.264597","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T19:18:16Z","timestamp":1685647096000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.122.264597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,1]]},"published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.2967\/jnumed.122.264597"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.122.264597","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,2]]}}}